Anika Therapeutics Inc Stock Price, News & Analysis

Anika Therapeutics (NASDAQ:ANIK) has reported topline results from its FastTRACK Phase III study for Hyalofast®, a cartilage repair scaffold. While the treatment showed consistent improvements over microfracture, it missed the pre-specified co-primary endpoints for KOOS Pain and IKDC function statistical significance.

Despite this setback, Hyalofast demonstrated statistically significant improvements in secondary endpoints, including KOOS Sports and Recreation Function, Quality of Life, and Total KOOS. The product has been successfully used in over 35,000 patients across 35+ countries since 2009. Anika plans to file the final PMA module in H2 2025, incorporating additional post-hoc analyses and global data under its Breakthrough Device Designation.

Anika Therapeutics (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, has scheduled its second quarter 2025 financial results announcement for Wednesday, July 30, 2025. The results will be released before market opening, followed by a conference call at 8:30 a.m. ET.

Investors can access the conference call via phone (toll-free: 1-800-717-1738 or international: 1-646-307-1865) using conference ID 48251. A live webcast and presentation materials will be available on Anika's investor relations website, with an archived version accessible after the call.

[]

Anika Therapeutics (NASDAQ: ANIK), a leader in osteoarthritis pain management and regenerative solutions, has announced inducement grants to a new non-executive employee. The company granted 2,500 non-statutory stock options at an exercise price of $10.53 per share on July 1, 2025.

The options were granted under the Anika Therapeutics 2021 Inducement Plan, with one-third of the shares vesting annually over three years, contingent on continuous service. The options will expire after ten years and were granted as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Anika Therapeutics (NASDAQ: ANIK) announced the granting of non-statutory stock options to a newly hired non-executive employee on June 2, 2025. The options cover 2,500 shares of common stock with an exercise price of $11.45, matching the closing price on Nasdaq Global Select Market on the grant date. The options were granted under the 2021 Inducement Plan as a material inducement for employment compensation. The vesting schedule spans three years, with one-third of shares vesting annually, contingent on continuous service. The options expire after ten years and were granted without stockholder approval.

Anika Therapeutics (NASDAQ: ANIK) announced the granting of non-statutory stock options to two newly hired non-executive employees on May 1, 2025. The options cover 5,000 shares of common stock at an exercise price of $14.46 per share, matching the closing price on the Nasdaq Global Select Market on the grant date. The options were granted under the company's 2021 Inducement Plan and will vest in three equal annual installments over three years, contingent on continuous service. The options expire after ten years and were approved as material inducement for employment compensation.

Anika Therapeutics (NASDAQ: ANIK) reported Q1 2025 financial results with mixed performance across channels. Commercial Channel revenue grew 18% to $11.3M, driven by the Integrity Implant System's success and international OA Pain Management growth. However, total revenue decreased 10% to $26.2M due to OEM Channel revenue declining 23% to $14.9M, affected by lower pricing for Monovisc and Orthovisc products. The company achieved key milestones for pipeline products, including Hyalofast PMA filing progress and FDA alignment on Cingal's NDA path. Operating expenses decreased 12% to $19.0M, while the company reported a loss of $4.0M from continuing operations. Anika updated its 2025 guidance, maintaining Commercial Channel revenue projections but lowering OEM Channel expectations to $62-65M (down 16-20% YoY) and adjusting Adjusted EBITDA guidance to -3% to 3%. The company completed its $15M share repurchase plan and maintains $53.4M in cash with no debt.

Anika Therapeutics (NASDAQ: ANIK), a leader in osteoarthritis pain management and regenerative solutions, has announced its participation in the upcoming Sidoti Virtual Investor Conference. The company's management will deliver a virtual presentation followed by a Q&A session on Wednesday, May 21, 2025, at 1:00 PM ET. Investors can access the live webcast through Anika's Investor Relations website section at www.anika.com, where an archived version will also be available for later viewing.

Anika Therapeutics (NASDAQ: ANIK), a global joint preservation company specializing in early intervention orthopedics, has scheduled the release of its first quarter 2025 financial results before market opening on Friday, May 9, 2025.

The company will host a conference call at 8:30 a.m. ET to discuss the results and business highlights. Investors can join via phone using toll-free domestic (1-800-717-1738) or international (1-646-307-1865) numbers with conference ID 63463. A live audio webcast with presentation materials will be available on Anika's website investor relations section.

Anika Therapeutics (NASDAQ: ANIK) has announced the granting of non-statutory stock options to a newly hired non-executive employee on April 1, 2025. The options cover 3,800 shares of common stock with an exercise price of $15.03 per share, matching the closing price on Nasdaq Global Select Market on the grant date.

The options were granted under the Anika Therapeutics 2021 Inducement Plan and approved by the compensation committee. The vesting schedule includes one-third of the shares vesting on each of the first three anniversaries of the grant date, contingent on continuous service. The options will expire after ten years and were granted as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).